Oncology News | pharmaphorum

News

EU regulator backs Idorsia’s Quviviq for adults with insomni...

A new treatment for adults with insomnia disorder has been recommended for use in Europe, giving hope to people whose lives are blighted by the condition.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

FDA approves Jardiance (empagliflozin) for wider range of pa...

Eli Lilly and Boehringer Ingelheim's blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart fa

News

Babraham Institute makes breakthrough in early human embryo ...

A new stem cell model, discovered by researchers exploring the human genome, will help scientists to map out the key genomic changes during early development.

News

Cantex secures license to develop small molecule-drug for in...

Clinical stage pharmaceutical company Cantex Pharmaceuticals has obtained a global licence from Harvard University’s Office of Technology Development to develop the small-molecule drug azel

News

GSK’s ZEJULA gets green light for NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer

News

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potenti

EU regulator backs Idorsia’s Quviviq for adults with insomni...

FDA approves Jardiance (empagliflozin) for wider range of pa...

Babraham Institute makes breakthrough in early human embryo ...

Cantex secures license to develop small molecule-drug for in...

GSK’s ZEJULA gets green light for NHS use

Big day for AZ, Daiichi as Enhertu aces HER2-low breast canc...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks